{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:52:52Z","timestamp":1783655572188,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Epilepsy patients with intellectual disability often suffer from drug-resistant epilepsy (DRE), which severely affects patients\u2019 quality of life. Cenobamate (CNB) is a recently approved novel and effective ASM that can achieve high rates of seizure freedom in previously drug-resistant patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective data analysis of the first patients treated with CNB at a single center. Outcome and treatment response were assessed at two different time points, and ASM burden was calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 12 patients (7 males and 5 females) began treatment at a median age of 43\u2009years, six of whom had developmental and epileptic encephalopathies. Prior to treatment with CNB, patients had tried a median of 13 different ASM. At the start of CNB therapy, patients were taking a median of 3 ASM. Treatment outcomes were available for 11 patients. After the first follow-up period (median 9\u2009months), 55% of patients showed a significant seizure reduction of more than 50%, with three patients showing a reduction of more than 75% (27%). One patient achieved complete seizure freedom, while one patient did not respond to treatment. These response rates were consistently maintained at second follow-up after a median of 22\u2009months. Ten patients (83%) reported adverse events (AE), the most common of which were dizziness and fatigue. No cases of drug reactions with eosinophilia and systemic symptoms (DRESS) were observed. The majority of AEs were mild and resolved over time. In addition, most patients were able to reduce their concomitant ASM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Cenobamate has been shown to be an effective ASM in patients with DRE and in patients with intellectual disabilities. After more than 1 year of treatment with CNB, close monitoring and management of drug\u2013drug interactions may reduce enzyme-inducing ASMs and lead to better long-term outcomes. With CNB treatment, many patients can achieve a reduced overall drug burden while maintaining a reduction in seizures.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1209487","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T02:57:40Z","timestamp":1689649060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction"],"prefix":"10.3389","volume":"14","author":[{"given":"Anna-Lena","family":"Friedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Greshake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin L.","family":"Makridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Beatus","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"ref1","author":"Elger","year":"2017"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/nejm200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"Ilae classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the Ilae task force on nosology and definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the Ilae task force on nosology and definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3238\/arztebl.2019.0809","article-title":"The medical care of people with intellectual disability","volume":"116","author":"Sappok","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/a-1400-1746","article-title":"Leave no one behind: intellectual disability and (mental) illness \u2013 a challenge for health care","volume":"48","author":"Sappok","year":"2021","journal-title":"Psychiatr Prax"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.seizure.2022.02.009","article-title":"Epilepsy surgery in the first six months of life: a systematic review and meta-analysis","volume":"96","author":"Makridis","year":"2022","journal-title":"Seizure"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1684\/epd.2022.1436","article-title":"Ictal Eeg recording is not mandatory in all candidates for paediatric epilepsy surgery with clear Mri lesions and corresponding seizure semiology","volume":"24","author":"Makridis","year":"2022","journal-title":"Epileptic Disord"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pediatrneurol.2023.03.020","article-title":"Is there a cognitive decline in pediatric patients following epilepsy surgery?","volume":"144","author":"Makridis","year":"2023","journal-title":"Pediatr Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"107809","DOI":"10.1016\/j.yebeh.2021.107809","article-title":"Effects of a specialized inpatient treatment program on epilepsy-related impairments of patients with epilepsy and intellectual disability as rated by relatives and professional caregivers","volume":"117","author":"Brandt","year":"2021","journal-title":"Epilepsy Behav"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00115-013-3961-y","article-title":"Mental disorders in the general population: study on the health of adults in Germany and the additional module mental health (Degs1-Mh)","volume":"85","author":"Jacobi","year":"2014","journal-title":"Nervenarzt"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1007\/s00415-023-11701-6","article-title":"Mortality risk in adults with intellectual disabilities and epilepsy: an England and Wales case-control study","volume":"270","author":"Sun","year":"2023","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"Cd005399","DOI":"10.1002\/14651858.CD005399.pub3","article-title":"Pharmacological interventions for epilepsy in people with intellectual disabilities","volume":"2015","author":"Jackson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.seizure.2016.07.001","article-title":"Guideline conform initial monotherapy increases in patients with focal epilepsy: a population-based study on German health insurance data","volume":"41","author":"Ertl","year":"2016","journal-title":"Seizure"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3205\/000250","article-title":"Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and Cross-sectional analysis of recently approved anti-epileptic drugs","volume":"15","author":"Groth","year":"2017","journal-title":"Ger Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3389\/fneur.2017.00712","article-title":"The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data","volume":"8","author":"Strzelczyk","year":"2017","journal-title":"Front Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","article-title":"Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fneur.2022.950171","article-title":"Real-world experience treating pediatric epilepsy patients with cenobamate","volume":"13","author":"Makridis","year":"2022","journal-title":"Front Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/wnl.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (Ykp 3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled","volume":"19","author":"Krauss","year":"2020","journal-title":"Dose-Response Trial Lancet Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (Ykp3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter","volume":"61","author":"Sperling","year":"2020","journal-title":"Open-Label Safety Study Epilepsia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/jcm12010129","article-title":"Treatment with Cenobamate in adult patients with Lennox-Gastaut syndrome: a case series","volume":"12","author":"Falcicchio","year":"2022","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"100533","DOI":"10.1016\/j.ebr.2022.100533","article-title":"Effectiveness and safety of adjunctive Cenobamate for focal seizures in adults with developmental disability treated in clinical practice","volume":"18","author":"Connor","year":"2022","journal-title":"Epilepsy Behav Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1111\/epi.17427","article-title":"Successful treatment of adult Dravet syndrome patients with Cenobamate","volume":"63","author":"Makridis","year":"2022","journal-title":"Epilepsia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of Cenobamate (Ykp3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal Ca3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"173117","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of Gaba(a) receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/analytica2030007","article-title":"Determination of Clobazam and its major metabolite N-Desmethylclobazam in human plasma with high-performance liquid chromatography","volume":"2","author":"Isse","year":"2021","journal-title":"Analytica"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40265-019-01250-6","article-title":"Cenobamate: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"9582","DOI":"10.3390\/ijms22179582","article-title":"Pharmacokinetic drug-drug interactions among antiepileptic drugs, including Cbd, drugs used to treat Covid-19 and nutrients","volume":"22","author":"Kara\u017aniewicz-\u0141ada","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/17512433.2021.1879637","article-title":"Cenobamate tablets as a treatment for focal-onset seizures in adults","volume":"14","author":"Steinhoff","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1080\/14656566.2020.1803830","article-title":"Cenobamate for the treatment of focal epilepsies","volume":"21","author":"Strzelczyk","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of Cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","article-title":"Efficacy and safety of adjunctive Cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant Antiseizure medications","volume":"96","author":"Brandt","year":"2022","journal-title":"Seizure"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1209487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T02:57:43Z","timestamp":1689649063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1209487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":33,"alternative-id":["10.3389\/fneur.2023.1209487"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1209487","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"article-number":"1209487"}}